Lipocine (LPCN) Shares Down 11.2%

Shares of Lipocine Inc (NASDAQ:LPCN) traded down 11.2% during mid-day trading on Tuesday . The stock traded as low as $1.55 and last traded at $1.58. 595,964 shares traded hands during trading, an increase of 3% from the average session volume of 578,200 shares. The stock had previously closed at $1.78.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Lipocine in a research note on Wednesday, May 15th.

The company has a market cap of $43.25 million, a price-to-earnings ratio of -2.87 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.37 and a quick ratio of 5.37.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, equities analysts forecast that Lipocine Inc will post -0.75 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Lipocine by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after purchasing an additional 35,000 shares during the period. Vanguard Group Inc boosted its stake in Lipocine by 4.9% during the 3rd quarter. Vanguard Group Inc now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after purchasing an additional 35,000 shares during the period. Renaissance Technologies LLC boosted its stake in Lipocine by 101.7% during the 1st quarter. Renaissance Technologies LLC now owns 406,700 shares of the specialty pharmaceutical company’s stock valued at $939,000 after purchasing an additional 205,100 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Lipocine during the 1st quarter valued at approximately $490,000. Finally, Spark Investment Management LLC bought a new stake in Lipocine during the 1st quarter valued at approximately $118,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/21/lipocine-lpcn-shares-down-11-2.html.

About Lipocine (NASDAQ:LPCN)

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.